Mechanism of Action
Bile Acid Synthesis Suppression
FGF-19 is released from ileal enterocytes when bile acids activate the farnesoid X receptor (FXR). Circulating FGF-19 binds FGFR4/beta-Klotho on hepatocytes, activating ERK1/2 to phosphorylate and inactivate SHP (small heterodimer partner), ultimately suppressing CYP7A1 (cholesterol 7-alpha hydroxylase), the rate-limiting enzyme in bile acid synthesis. This FXR-FGF-19-CYP7A1 axis is the primary feedback loop controlling bile acid pool size and composition.
Hepatic Metabolic Reprogramming
Beyond bile acid regulation, FGF-19 activates FGFR4/beta-Klotho signaling to suppress hepatic gluconeogenesis (via CREB/PGC-1alpha suppression), promote glycogen synthesis, reduce de novo lipogenesis (SREBP-1c downregulation), and increase fatty acid oxidation. In contrast to insulin, FGF-19 activates PI3K/Akt for anabolic effects while simultaneously activating MAPK/ERK for gene expression changes, providing a unique metabolic dual action that improves both glucose and lipid metabolism.
Energy Expenditure and Body Composition
FGF-19 increases energy expenditure by activating thermogenesis in brown and beige adipose tissue via FGFR1/beta-Klotho. In skeletal muscle, FGF-19 promotes mitochondrial biogenesis and shifts substrate utilization toward fatty acid oxidation. These peripheral effects, combined with central appetite-modulating actions via hypothalamic FGFR1, make FGF-19 a powerful anti-obesity signal that increases metabolic rate without reducing food intake substantially.
Research Summary
NASH/MASH (Phase III)
ClinicalAldafermin, an engineered FGF-19 analogue with reduced FGFR4-mediated hepatocellular proliferation risk, completed Phase II trials for NASH showing significant reductions in liver fat (MRI-PDFF), ALT, and fibrosis biomarkers. Phase III trials (ALPINE program) are ongoing. Native FGF-19 itself causes hepatocellular carcinoma (HCC) in mice via FGFR4 overactivation, necessitating the engineered analogue approach.
Cholestatic Liver Disease
ClinicalIn primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), where bile acid homeostasis is disrupted, FGF-19/aldafermin reduces elevated bile acid levels and improves liver enzyme profiles. The FXR agonist obeticholic acid (approved for PBC) partly works by inducing endogenous FGF-19 production, validating the therapeutic axis.
Bariatric Surgery Mechanism
TranslationalPostprandial FGF-19 levels rise dramatically after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy, correlating with improved insulin sensitivity, reduced liver fat, and weight-independent metabolic benefits. FGF-19 may be one of the key gut hormones mediating the metabolic improvements of bariatric surgery that exceed those expected from weight loss alone.
Calculate your FGF-19 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| NASH metabolic improvement | 1-3 mg/kg SC aldafermin | Once daily x 12-24 weeks | SC (clinical reference) |
| Bile acid suppression (animal) | 0.1-1 mg/kg IV | Single or daily x 5 days | IV or SC |
| Body composition study | 1 mg/kg SC | Daily x 4 weeks | SC (preclinical) |
Native FGF-19 carries HCC risk in rodents at chronic pharmacological doses due to FGFR4 overactivation. Clinical development uses engineered analogue aldafermin (NGM282).
Interactions
Safety Profile
Native FGF-19 causes hepatocellular carcinoma in transgenic mice via chronic FGFR4 overactivation, prompting development of the engineered analogue aldafermin that retains metabolic activity while reducing mitogenic signaling. Aldafermin clinical trials show generally good tolerability; most common adverse events are GI (nausea, diarrhea) and injection site reactions. Liver enzyme elevation occurs in a minority of patients. Long-term HCC risk in humans is being monitored in ongoing trials. Diarrhea from reduced bile acid synthesis-driven fat malabsorption is dose-dependent.
References
- [1]Inagaki T, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005.
- [2]Harrison SA, et al. Aldafermin in nonalcoholic steatohepatitis: ALPINE Phase 2b. N Engl J Med. 2021.
- [3]Kir S, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science. 2011.